Cepi-u.s.

Based in DC

🤖

AI Overview

With $1.4M in lobbying spend across 40 quarterly filings, Cepi-u.s is a significant lobbying presence. Their lobbying covers 3 issue areas. Active from 2018 to 2025.

$1.4M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$28K
2019	$28K
2020	$253K
2021	$160K
2022	$200K
2023	$220K
2024	$210K
2025	$260K

Issues Lobbied

Health Issues Budget/Appropriations Foreign Relations

Lobbying Firms

Cepi-u.s.

Lobbyists

Dawn O'connell Richard Hatchett Richard Wilder Daniel Skallman

Government Agencies Targeted

These are the government entities that Cepi-u.s. disclosed contacting in their lobbying filings.

Defense, Dept of (DOD)HOUSE OF REPRESENTATIVESNatl Security Council (NSC)SENATEU.S. Agency for International Development (USAID)Office of Management & Budget (OMB)Health & Human Services, Dept of (HHS)White House OfficeState, Dept of (DOS)Overseas Private Investment Corp (OPIC)Treasury, Dept ofHomeland Security, Dept of (DHS)Food & Drug Administration (FDA)Office of Science & Technology Policy (OSTP)Natl Institutes of Health (NIH)Centers For Disease Control & Prevention (CDC)

View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Budget/Appropriations, Foreign Relations

Appropriations for CEPI Norway, Pandemics and All-Hazards Preparedness Reauthorization.

Appropriations for CEPI Norway, Pandemics and All-Hazards Preparedness Reauthorization, possible addition of MERS/Lassa/Nipah to FDA's Priority Review Voucher program.

Appropriations for CEPI Norway, Pandemics and All-Hazards Preparedness Reauthorization, possible addition of MERS//Nipah/Rift Valley Fever to FDA's Priority Review Voucher program.

Request for Member support of appropriations from USAID to CEPI. Also support for a bill that will update Neglected Tropical Disease Priority Review Vouchers at FDA. Being drafted (and soon introduc